{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:59:34Z","timestamp":1789466374816,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research","doi-asserted-by":"crossref","award":["FRN111627, FDN148469"],"award-info":[{"award-number":["FRN111627, FDN148469"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000243","name":"W. Garfield Weston Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jconrel.2018.07.026","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T14:50:19Z","timestamp":1531839019000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids"],"prefix":"10.1016","volume":"286","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3738-6600","authenticated-orcid":false,"given":"Sam","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Zaifman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor V.","family":"Zhigaltsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying K.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Ciufolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen Yi C.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter R.","family":"Cullis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.07.026_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2007.06.012","article-title":"Innate immune response induced by gene delivery vectors","volume":"354","author":"Sakurai","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-immunol-031210-101340","article-title":"Nucleic acid recognition by the innate immune system","volume":"29","author":"Barbalat","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0015","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.4049\/jimmunol.163.3.1552","article-title":"Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously","volume":"163","author":"Dow","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0020","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/sj.gt.3301026","article-title":"LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth","volume":"6","author":"Whitmore","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0025","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0022-3565(24)29491-X","article-title":"Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles","volume":"298","author":"Mui","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2018.07.026_bb0030","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle Systems for Enabling Gene Therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0035","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.addr.2012.06.007","article-title":"Safety profile of RNAi nanomedicines","volume":"64","author":"Barros","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/mt.2009.208","article-title":"Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment","volume":"18","author":"Abrams","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0045","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1038\/mtna.2014.61","article-title":"Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, Cytokine induction, and efficacy","volume":"3","author":"Kumar","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0050","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nano.2011.06.003","article-title":"Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome","volume":"8","author":"Szebeni","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0055","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev-chembioeng-061010-114133","article-title":"Silencing or stimulation? siRNA delivery and the immune system","volume":"2","author":"Whitehead","year":"2011","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0065","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1089\/hum.2008.131","article-title":"Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation","volume":"19","author":"Robbins","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nbt1081","article-title":"Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA","volume":"23","author":"Judge","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0075","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/jpet.104.078113","article-title":"Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid","volume":"312","author":"Semple","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0080","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jconrel.2009.10.017","article-title":"CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes","volume":"142","author":"Tagami","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2010.12.013","article-title":"Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA","volume":"151","author":"Tagami","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0090","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","article-title":"Glucocorticoid use in acute lymphoblastic leukemia: comparison of prednisone and dexamethasone","volume":"11","author":"Inaba","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0095","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/leu.2011.84","article-title":"Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"25","author":"Teuffel","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1191\/096120301675075008","article-title":"Treatment of lupus with corticosteroids","volume":"10","author":"Chatham","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0105","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids \u2014 new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.65","article-title":"Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain","volume":"2","author":"Rungta","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0120","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0125","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0130","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00262-006-0276-x","article-title":"Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN","volume":"56","author":"de Jong","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0135","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.intimp.2007.04.002","article-title":"Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles","volume":"7","author":"Wilson","year":"2007","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0140","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ymeth.2012.09.004","article-title":"Methods for studying IRES-mediated translation of positive-strand RNA viruses","volume":"59","author":"Wang","year":"2013","journal-title":"Methods"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0150","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11095-004-1873-z","article-title":"A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA","volume":"22","author":"Jeffs","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0155","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2014.09.025","article-title":"Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration","volume":"196C","author":"Chen","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0165","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.nano.2016.12.014","article-title":"Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA","volume":"13","author":"Kulkarni","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0170","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/y59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh","year":"1959","journal-title":"Can. J. Biochem. Physiol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0175","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jhep.2013.05.045","article-title":"Liver as a target for oligonucleotide therapeutics","volume":"59","author":"Sehgal","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0180","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0185","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0190","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ymthe.2005.11.002","article-title":"Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo","volume":"13","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0195","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1261\/rna.1901810","article-title":"Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs","volume":"16","author":"Ge","year":"2010","journal-title":"RNA"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0200","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0005-2736(95)00268-5","article-title":"Fate of cationic liposomes and their complex with oligonucleotide in vivo","volume":"1281","author":"Litzinger","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0210","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/mt.2011.190","article-title":"Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells","volume":"19","author":"Basha","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10517-011-1457-y","article-title":"Comparative analysis of esterase activities of human, mouse, and rat blood","volume":"152","author":"Rudakova","year":"2011","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0220","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/187231209788654081","article-title":"Esterase activities in the blood, liver and intestine of several preclinical species and humans","volume":"3","author":"Berry","year":"2009","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0225","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.nano.2012.11.006","article-title":"Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA","volume":"9","author":"Tam","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0230","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0235","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0240","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0245","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2015.103","article-title":"Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals","volume":"23","author":"Thess","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2018.07.026_bb0255","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1093\/nar\/gkr586","article-title":"Nucleoside modifications in RNA limit activation of 2\u2032-5\u2032-oligoadenylate synthetase and increase resistance to cleavage by RNase L","volume":"39","author":"Anderson","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0260","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0265","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0270","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nbt.1733","article-title":"Expression of therapeutic proteins after delivery of chemically modified mRNA in mice","volume":"29","author":"Kormann","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0275","first-page":"239","article-title":"Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus","volume":"1","author":"Cotten","year":"1994","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0280","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/hum.1995.6.3-317","article-title":"Bacterial lipopolysaccharide copurifies with plasmid DNA: implications for animal models and human gene therapy","volume":"6","author":"Wicks","year":"1995","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2018.07.026_bb0285","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","article-title":"Side effects of corticosteroid therapy","volume":"33","author":"Buchman","year":"2001","journal-title":"J. Clin. Gastroenterol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918304206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918304206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:35:17Z","timestamp":1759160117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918304206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":57,"alternative-id":["S0168365918304206"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.07.026","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}